甲状腺功能亢进症治疗方法的比较和选择

汤建林; 李玉莹; 高柳艳; 唐秀萍; 胡红永; 汤建林; 李玉莹; 高柳艳; 唐秀萍; 胡红永

doi:10.3760/cma.j.issn.1673-4114.2009.03.012

[1]

邢家骝.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002.152-176.

[2]

高妍.应用基础研究指导临床实践,提高Graves病的长期缓解率.中华内分泌代谢杂志,1995,11(3):131-132.

[3]

医学会内分泌学分会《中目甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南-甲状腺功能亢进症.中华内科杂志,2007,46(10):876-882.

[4]

高妍.Graves病诊治中的几个问题.中华内分泌代谢杂志,2001,17(4):193-194.

[5]

田硕涵,周颖.抗甲状腺药的进展与应用评价.中国医院用药评价与分析,2008,8(6):410-411.

[6]

杨春明.甲状腺功能亢进的外科治疗.中国普通外科杂志,2007,16(1):4-6.

[7]

Rudberg C, Johansson H, Akerstr? m G, et al. Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol, 1996, 134(6):710-715.

[8]

匡安仁.内分泌疾病的治疗//张永学.核医学.北京:人民卫生出版社,2005:353-358.

[9]

Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA, 1998, 280(4):347-355.

[10]

邢家骝.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002:145-151.

[11]

卢倜章.甲状腺功能亢进症//马寄晓,刘秀杰.实用临床医学.2版.北京:原子能出版社,2002,471-482.

[12]

邢家骝.¹³¹Ⅰ治疗甲状腺功能亢进症对性腺的影响.中华内分泌代谢杂志,2007,23(6):481-483.

[13]

[No authors listed]. Summary of current radiation close estimates to humans from ¹²³I, ¹²⁴I, ¹²⁵I,¹²⁶I,¹³⁰I,¹³¹I, and ¹³²I as sodium iodide. J Nucl Med, 1975, 16(9):857-860.

[14]

ICRP-53. Radioation dose to patients from radiopharmaceuticals. Ann ICRP, 1987, 18(1-4):1-29.

[15]

Stabin MG, Stubbs JB, Toohey RE. Radioation dose estimates for radiopharmaceuticals. ORISE Document, April 30,1996,available at www.orise.orau.gov/reacts.

[16]

邢家骝.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002:50-52.

[17]

Berg GE, Michanek AM, Holmberg EC, et al. Iodine-131 treatment of hyperthyroidism:significance deflective half-life measurements. J Nucl Med, 1996,37(2):228-232.

[18]

Rivkees SA, Sklar C, Frecmark M. Clinical review 99:The management of Graves' disease in chihtren, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab, 1998, 83(11):3767-3776.

[19]

陈敏,周翔天,盛文,等.甲状腺相关性眼病研究治疗新进展.国际眼科杂志,2006,6(4):875-878.

[20]

Read CH Jr, Tansey M J, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endoerinol Metab, 2004, 89(9):4229-4233.

[21]

陈文贤,颜兵.抗甲状腺药物和131碘治疗甲亢的医疗成本分析.中国卫生事业管理,1999,15(6):302-305.

[22]

Singer PA, Cooper DS, Levy EC, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA, 1995, 273(10):808-812.

[23]

Arbelle JE, Porath A. Practice guidelines for the detection and management of thyroid dysfunction, A comparative review of the recommendations. Clin Endocrinol, 1999, 51(1):11-18.

[24]

Wartoisky L. Radiniodine therapy for Graves disease:ease selection and restrictions recommended to patients in North America. Thyroid, 1997, 7(2):213-216.